|
|
Volumn 17, Issue 3, 2018, Pages 153-155
|
|
Oncologists tap the microbiome in bid to improve immunotherapy outcomes
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
CYTOTOXIC T LYMPHOCYTE ANTIGEN 4;
CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY;
PEMBROLIZUMAB;
PROBIOTIC AGENT;
PROGRAMMED DEATH 1 LIGAND 1;
PROGRAMMED DEATH 1 RECEPTOR;
SER 401;
ANTIINFECTIVE AGENT;
IMMUNOLOGIC FACTOR;
AKKERMANSIA MUCINIPHILA;
ANTINEOPLASTIC ACTIVITY;
ARTICLE;
BACTERIUM;
BACTEROIDES;
BIFIDOBACTERIUM;
BIFIDOBACTERIUM LONGUM;
CANCER IMMUNOLOGY;
CANCER IMMUNOTHERAPY;
CLOSTRIDIUM DIFFICILE INFECTION;
DRUG INDUSTRY;
FECAL MICROBIOTA TRANSPLANTATION;
FECES MICROFLORA;
HUMAN;
MELANOMA;
MICROBIOME;
NONHUMAN;
ONCOLOGIST;
OUTCOME ASSESSMENT;
PRIORITY JOURNAL;
RUMINOCOCCACEAE;
IMMUNOLOGY;
IMMUNOTHERAPY;
MICROBIOLOGY;
MICROFLORA;
NEOPLASM;
PROCEDURES;
ANTI-BACTERIAL AGENTS;
HUMANS;
IMMUNOLOGIC FACTORS;
IMMUNOTHERAPY;
MICROBIOTA;
NEOPLASMS;
ONCOLOGISTS;
|
|
EID: 85042654568
PISSN: 14741776
EISSN: 14741784
Source Type: Journal
DOI: 10.1038/nrd.2018.19 Document Type: Article |
|
Times cited : (16)
|
|
References (0)
|